| Diabetes has been listed as one of the three major chronic diseases that seriously harm humans and pets.The death rate is second only to cancer and cardiovascular diseas.At present,the main clinical treatment of diabetes is exercise,drug,pancreas and islet cell transplantation,but this often involves adverse reactions such as the development of organism resistance and side effects.Pathologically,pancreatic stem cells have been shown to proliferate and differentiate into functional beta cells that secrete insulin.This brings new hope for the cure of clinical diabetes.In this study,the diabetic rat model was prepared to detect the therapeutic effect of taurine on type I diabetes,and the mechanism was discussed from the perspective of promoting the proliferation and differentiation of pancreatic stem cells,so as to provide certain reference for the clinical treatment of diabetes.The research content of this paper includes the in vivo and the in vitro experiments.The in vivo experiment:Eighty SPF male rats were selected,and 60 rats were randomly selected to prepare the diabetes model by intraperitoneal injection of 50 mg/kg STZ and tested the fasting blood glucose values after 7 days.According to the internationally accepted standard,the diabetes model was successfully established with a fasting blood glucose level greater than 16.7 mmol/L.The rats were then randomly divided into five groups:Normal group(C),Taurine control group(T),Diabetes model group(M),Taurine treatment group 1(MT1),Taurine treatment group 2(MT2).Rats were continuously fed for 8 weeks,and behavioral changes,fasting blood glucose and body weight changes were observed and recorded.Oral glucose tolerance test was conducted one week before the rats were put to death to test the sugar load capacity of the animal body.At the end of the experiment,the rats were put to death and their serum levels of Insulin,Glucagon and C-peptide were measured.The pancreatic tissue of rats was collected and the histomorphological changes of islets were observed by HE staining,he expression of insulin and glucagon positive cells were detected by immunofluorescence staining.The in vitro experiment:Rat pancreatic stem cells were isolated and cultured by mechanical digestion.After Nestin immunohistochemical identification,the cells were divided into control group(group A)and taurine group(group B).Islet cells were induced by adding induction medium and identified by DTZ staining.We choosed the cells from the third generation to extract the total protein,and detected the expression levels of important regulatory factors TLR4,RIP1,NF-κB P50 and NF-κB P65 in pancreatic stem cell by western-blot analysis.The results showed that:Continuous administration of taurine in diabetic rats can significantly improve the typical symptoms of diabetes and significantly reduce blood glucose levels.The levels of serum insulin and C-peptide in the taurine-treated rats were significantly higher than those in the model group,and the content of glucagon was significantly decreased.The results of immunofluorescence staining showed that compared with the model group,the expression of insulin was significantly increased and the expression of glucagon was significantly decreased in the taurine treatment group.The results of oral glucose tolerance showed that the sugar load capacity of taurine treatment group was significantly improved.In cell experiments,stem cells extracted from diabetic rat ductal epithelium were identified as pancreatic stem cells by immunocytochemistry.The formation of islet β cells was confirmed by DTZ staining after adding induction differentiation medium.The expression of key proteins TLR4,RIP1,NF-κB p50,NF-κB p65 in pancreatic stem cell proliferation-related pathways were significantly increased by Western blot.Combine the above results,it indicates that taurine can improve the typical clinical symptoms of diabetic rats,improve the body’s sugar load capacity and promote insulin secretion.Then it also can promote the proliferation of pancreatic stem cells and induce differentiation by acting on NF-κB signaling pathway. |